Intervention Protocol

Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy

  1. Lior H Katz1,*,
  2. Abigail Fraser2,
  3. Leonard Leibovici3,
  4. Rani Tur-Kaspa4

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 15 APR 2009

Assessed as up-to-date: 23 SEP 2008

DOI: 10.1002/14651858.CD005264.pub2


How to Cite

Katz LH, Fraser A, Leibovici L, Tur-Kaspa R. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD005264. DOI: 10.1002/14651858.CD005264.pub2.

Author Information

  1. 1

    Sheba Medical Center, Gastroenterology Department, Ramat-Gan, Israel

  2. 2

    University of Bristol, Oakfield House, Department of Social Medicine, MRC Centre for Causal Analysis in Translational Epidemiology, Bristol, UK

  3. 3

    Beilinson Campus, Rabin Medical Center, Department of Medicine E, Petah-Tiqva, Israel

  4. 4

    Rabin Medical Center - Beilison Campus, Department of Internal Medicine D, Petah Tigva, Israel

*Lior H Katz, Gastroenterology Department, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, 52621, Israel. liorshlomit@yahoo.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 APR 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of lamivudine in preventing reactivation of HBV during or following immunosuppressive therapy in HBsAg-positive patients.

To estimate the optimal time of initiating lamivudine prophylactic therapy in HBsAg-positive patients receiving immunosuppressive therapy.